<p>Data points represent binding activity for scFv J4 on individual serum samples. Two outliers in control group that demonstrated high binding activity are circled. C - non-cancerous control sample, Ad1-stage 1 adenocarcinoma.</p
<p>A) Histograms demonstrating surface binding of the indicated antibodies, either commercial mAb5T4...
<p>Mean fluorescence intensities (MFI) of FACS-based binding assay for neutralizing (VRC01, 10E8, PG...
bound to case-pool serum. The enriched yeast-display scFv were labeled with anti-c-myc mAb and 25 μg...
<p><b>A</b> Biotinylated scFv immobilized onto streptavidin-coated microtiter wells were used to cap...
<p><b>A.</b> Anti-human IgM - specific antibodies immobilized onto beads were used to capture IgM fr...
<p>Binding of surrogate scFv was measured by ELISA using horseradish peroxidase-conjugated anti-His-...
<p>ScFv binding activity was determined by a fluorescent (FMAT) assay. Each bar represents the mean ...
<p>Binding of purified scFvs to L1/ecd, Ig1–4, Fn1–3 was determined by ELISA. (<b>A</b>) ScFv I4, (<...
Time resolution of on-cell sCD4 triggering of BaL.01 Env. Binding efficacy of V3 crown mAb 1–79 (A, ...
<p>Binding of Fc-linked surrogate scFv was measured by ELISA using horseradish peroxidase-conjugated...
New anti-cancer agents are being developed that specifically recognise tumour cells. Recognition is ...
<p>A. Representative LC-MS chromatograms of a IgG sepharose-binding molecule (m/z 1414.3) are shown ...
<p>(<b>a</b>, <b>b</b>) Analysis of dissociation rates in the cell surface retention assay <i>in vit...
<p>Binding ELISA testing subject 16Ms plasma against normal human plasma and four monoclonal antibod...
On-cell sCD4 triggering of MN.3, BaL.01, JR-FL, and BG505_T332N Envs and assessment of antibody/inhi...
<p>A) Histograms demonstrating surface binding of the indicated antibodies, either commercial mAb5T4...
<p>Mean fluorescence intensities (MFI) of FACS-based binding assay for neutralizing (VRC01, 10E8, PG...
bound to case-pool serum. The enriched yeast-display scFv were labeled with anti-c-myc mAb and 25 μg...
<p><b>A</b> Biotinylated scFv immobilized onto streptavidin-coated microtiter wells were used to cap...
<p><b>A.</b> Anti-human IgM - specific antibodies immobilized onto beads were used to capture IgM fr...
<p>Binding of surrogate scFv was measured by ELISA using horseradish peroxidase-conjugated anti-His-...
<p>ScFv binding activity was determined by a fluorescent (FMAT) assay. Each bar represents the mean ...
<p>Binding of purified scFvs to L1/ecd, Ig1–4, Fn1–3 was determined by ELISA. (<b>A</b>) ScFv I4, (<...
Time resolution of on-cell sCD4 triggering of BaL.01 Env. Binding efficacy of V3 crown mAb 1–79 (A, ...
<p>Binding of Fc-linked surrogate scFv was measured by ELISA using horseradish peroxidase-conjugated...
New anti-cancer agents are being developed that specifically recognise tumour cells. Recognition is ...
<p>A. Representative LC-MS chromatograms of a IgG sepharose-binding molecule (m/z 1414.3) are shown ...
<p>(<b>a</b>, <b>b</b>) Analysis of dissociation rates in the cell surface retention assay <i>in vit...
<p>Binding ELISA testing subject 16Ms plasma against normal human plasma and four monoclonal antibod...
On-cell sCD4 triggering of MN.3, BaL.01, JR-FL, and BG505_T332N Envs and assessment of antibody/inhi...
<p>A) Histograms demonstrating surface binding of the indicated antibodies, either commercial mAb5T4...
<p>Mean fluorescence intensities (MFI) of FACS-based binding assay for neutralizing (VRC01, 10E8, PG...
bound to case-pool serum. The enriched yeast-display scFv were labeled with anti-c-myc mAb and 25 μg...
DOI
Add to ORKG